CN112368017A - HSV-2-DELTA-gD疫苗及其生产和使用方法 - Google Patents

HSV-2-DELTA-gD疫苗及其生产和使用方法 Download PDF

Info

Publication number
CN112368017A
CN112368017A CN201980044626.3A CN201980044626A CN112368017A CN 112368017 A CN112368017 A CN 112368017A CN 201980044626 A CN201980044626 A CN 201980044626A CN 112368017 A CN112368017 A CN 112368017A
Authority
CN
China
Prior art keywords
hsv
subject
antigen
amount
recombinant
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201980044626.3A
Other languages
English (en)
Chinese (zh)
Inventor
威廉·雅各布斯
贝琪·赫罗尔德
约瑟夫·达迪克
凯拉·A·韦斯
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Albert Einstein College of Medicine
Original Assignee
Albert Einstein College of Medicine
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Albert Einstein College of Medicine filed Critical Albert Einstein College of Medicine
Publication of CN112368017A publication Critical patent/CN112368017A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/245—Herpetoviridae, e.g. herpes simplex virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/13—Labelling of peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C12N15/102—Mutagenizing nucleic acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5256—Virus expressing foreign proteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16611—Simplexvirus, e.g. human herpesvirus 1, 2
    • C12N2710/16634—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16611—Simplexvirus, e.g. human herpesvirus 1, 2
    • C12N2710/16641—Use of virus, viral particle or viral elements as a vector
    • C12N2710/16643—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
    • C12N2740/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
    • C12N2740/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Virology (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Mycology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Analytical Chemistry (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
CN201980044626.3A 2018-05-01 2019-05-01 HSV-2-DELTA-gD疫苗及其生产和使用方法 Pending CN112368017A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862665050P 2018-05-01 2018-05-01
US62/665,050 2018-05-01
PCT/US2019/030259 WO2019213305A1 (en) 2018-05-01 2019-05-01 HSV-2-DELTA-gD VACCINES AND METHODS FOR THEIR PRODUCTION AND USE

Publications (1)

Publication Number Publication Date
CN112368017A true CN112368017A (zh) 2021-02-12

Family

ID=68386663

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201980044626.3A Pending CN112368017A (zh) 2018-05-01 2019-05-01 HSV-2-DELTA-gD疫苗及其生产和使用方法

Country Status (8)

Country Link
US (2) US20210236625A1 (https=)
EP (1) EP3787680A4 (https=)
JP (2) JP7671982B2 (https=)
CN (1) CN112368017A (https=)
AU (1) AU2019262056B2 (https=)
CA (1) CA3098572A1 (https=)
IL (1) IL278294B2 (https=)
WO (1) WO2019213305A1 (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113430178A (zh) * 2021-06-21 2021-09-24 武汉大学 一种表达ii型单纯疱疹病毒蛋白的重组流感病毒株及其制备方法与应用

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2024145863A1 (en) * 2023-01-05 2024-07-11 Virogin Biotech (Shanghai) Ltd. A NOVEL mRNA VACCINE FOR THE TREATMENT AND PREVENTION OF HPV-ASSOCIATED LESIONS AND TUMORS
CN116497049B (zh) * 2023-05-04 2024-03-22 江苏三仪生物工程有限公司 一种表达犬疱疹病毒gD糖基化蛋白的重组菌及其应用

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1425073A (zh) * 2000-01-21 2003-06-18 拜奥维克斯有限公司 病毒株
US20170202952A1 (en) * 2014-03-03 2017-07-20 Albert Einstein College Of Medicine, Inc Recombinant herpes simplex virus 2 (hsv-2) vaccine vectors

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0326798D0 (en) * 2003-11-17 2003-12-24 Crusade Lab Ltd Methods for generating mutant virus
US20070003520A1 (en) 2003-11-17 2007-01-04 Brown Susanne M Mutant viruses
CA2587084C (en) * 2004-10-08 2019-07-16 The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services, Centers For Disease Control And Prevention Modulation of replicative fitness by using less frequently used synonym ous codons
WO2008027394A2 (en) * 2006-08-28 2008-03-06 The Wistar Institute Of Anatomy And Biology Constructs for enhancing immune responses
TR201802741T4 (tr) * 2010-05-14 2018-03-21 Univ Oregon Health & Science Rekombinant hcmv ve rhcmv vektörleri ve bunların kullanımları.

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1425073A (zh) * 2000-01-21 2003-06-18 拜奥维克斯有限公司 病毒株
US20170202952A1 (en) * 2014-03-03 2017-07-20 Albert Einstein College Of Medicine, Inc Recombinant herpes simplex virus 2 (hsv-2) vaccine vectors

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
AR DAVIS, ET AL: "High throughput method for creating and screening recombinant adenoviruses", GENE THERAPY, vol. 5 *
CHRISTOPHER PETRO, ET AL: "Herpes simplex type 2 virus deleted in glycoprotein D protects against vaginal, skin and neural disease", ELIFE, vol. 4, pages 13 *
JOSEPH DARDICK, ET AL: "A novel vaccine vector: herpes simplex virus type-2 deleted in glycoprotein D (HSV-2 ΔgD) andexpressing modified influenza A (IAV) hemagglutinin (HA) antigens", THE JOURNAL OF IMMUNOLOGY, vol. 198, no. 1, pages 1 - 2 *
徐智勇等: "质粒剂量和免疫次数 对基因枪免疫DNA疫苗免疫反应的影响", 中国生物制品学杂志, vol. 23, no. 6 *

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113430178A (zh) * 2021-06-21 2021-09-24 武汉大学 一种表达ii型单纯疱疹病毒蛋白的重组流感病毒株及其制备方法与应用
CN113430178B (zh) * 2021-06-21 2022-10-11 武汉大学 一种表达ii型单纯疱疹病毒蛋白的重组流感病毒株及其制备方法与应用

Also Published As

Publication number Publication date
IL278294B1 (en) 2024-09-01
US12150986B2 (en) 2024-11-26
JP2025032104A (ja) 2025-03-11
AU2019262056A1 (en) 2020-10-29
US20230293674A1 (en) 2023-09-21
IL278294A (en) 2020-12-31
AU2019262056B2 (en) 2025-10-02
JP7671982B2 (ja) 2025-05-07
EP3787680A4 (en) 2022-06-22
CA3098572A1 (en) 2019-11-07
IL278294B2 (en) 2025-01-01
WO2019213305A1 (en) 2019-11-07
US20210236625A1 (en) 2021-08-05
EP3787680A1 (en) 2021-03-10
JP2021522854A (ja) 2021-09-02

Similar Documents

Publication Publication Date Title
JP7113924B2 (ja) 組み換え改変ワクシニアウイルスアンカラ（ｍｖａ）フィロウイルスワクチン
CN107921117B (zh) Hpv疫苗
AU2014359276B2 (en) CMV vaccines
JP5123343B2 (ja) Ｈｉｖｃｏｎ：ｈｉｖ免疫原及びその使用
US9610346B2 (en) Recombinant viral vectors
US12150986B2 (en) HSV-2-delta-gD vaccines and methods for their production and use
US20190307879A1 (en) Adenovirus-vectored multivalent vaccine
KR20230016193A (ko) 베타코로나바이러스에 대한 면역화를 위한 바이러스 백신 벡터
HRP970092A2 (en) Synthetic hiv genes
EP2644701B1 (en) Methods to improve vector expression and genetic stability
CN106794240A (zh) 重组伊斯法罕病毒载体
JP4418101B2 (ja) 遺伝子ワクチンのための弱毒化ｖｉｆＤＮＡ免疫化カセット
CN109641044A (zh) 用于产生对乙型肝炎病毒的免疫应答的组合物和方法
CN115925910A (zh) 经修饰的hiv-1用于产生完全人抗体的用途
US9707290B2 (en) Immunogens of HIV-1 broadly neutralizing antibodies, methods of generation and uses thereof
JP2017534284A (ja) 最適化ＨＩＶ遺伝子を含有及び発現する遺伝的に安定な複製可能センダイ（Ｓｅｎｄａｉ）ウイルスベクター
US20250026794A1 (en) Methods of preventing, treating, or reducing the severity of coronavirus disease 2019 (covid-19)
HK40046147A (en) Hsv-2-delta-gd vaccines and methods for their production and use
WO2024026378A2 (en) HSV GENE EXPRESSION VECTOR AND BxB1 INTEGRASE-MEDIATED RECOMBINATION SYSTEM FOR HIGH-THROUGHPUT CLONING
HK40082300A (en) Hpv vaccines
WO2023245159A1 (en) Recombinant herpes simplex virus 2 (hsv-2) vectors and engineered transgenic vero cell lines
Potent Characterization of Nonpathogenic, Live
HK40014682B (zh) 新的对抗寨卡病毒的疫苗和用於对抗寨卡病毒的dna抗体构建体的组合
JP2004002343A (ja) Ｈｉｖ−１に対する新規多価ｄｎａワクチン

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 40046147

Country of ref document: HK